Preferred Noninvasive Testing for Nonalcoholic Steatohepatitis

Background There has been an increased interest in the use of noninvasive tests (NITs) to identify advanced liver fibrosis in patients with nonalcoholic fatty liver disease (NALFD). The aim of our study was to define the change in tests’ characteristics (sensitivity and specificity) of different com...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Digestive diseases and sciences 2020-12, Vol.65 (12), p.3719-3725
Hauptverfasser: Le, Long, Kullar, Ravina, Saleh, Hussein M., Saab, Sammy
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 3725
container_issue 12
container_start_page 3719
container_title Digestive diseases and sciences
container_volume 65
creator Le, Long
Kullar, Ravina
Saleh, Hussein M.
Saab, Sammy
description Background There has been an increased interest in the use of noninvasive tests (NITs) to identify advanced liver fibrosis in patients with nonalcoholic fatty liver disease (NALFD). The aim of our study was to define the change in tests’ characteristics (sensitivity and specificity) of different combinations of NITs to detect advanced fibrosis in NAFLD. Methods We stratified NITs into first and second tiers and compared two different strategies of combining NITs to screen for advanced fibrosis in patients with NAFLD. One strategy was using NITs in parallel, and the other was using NITs sequentially. Within both of these strategies, there were two ways of interpreting the overall results. The first way was called “the AND rule,” where a positive result required both individual test results to be positive. The second way was called “the OR rule,” where a positive result required only one individual test to be positive. Accuracy of NITs was obtained from the literature search. Combined accuracy and likelihood ratio (LR) were calculated. Results Combination testing with parallel and sequential order testing under the AND Rule resulted in overall higher specificity and LR+ then using the NITs alone. Specificity ranged from 0.91 to 0.99, and LR+ from 9.3 to 68.6. The subsequent use of MRE was associated with LR+ between 36 and 69. Sensitivity was higher with parallel and sequential order testing under the OR Rule. LR+ ranged from 1.4 to 7.5, and sensitivity from 0.82 to 0.98. Conclusion Screening for advanced fibrosis should be performed sequentially, with positive results confirmed by additional testing. Specificity and LR+ were highest when MRE was employed as the confirmatory test.
doi_str_mv 10.1007/s10620-020-06382-4
format Article
fullrecord <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_2424448005</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A712935137</galeid><sourcerecordid>A712935137</sourcerecordid><originalsourceid>FETCH-LOGICAL-c442t-33c2d534fb27dcc1ba94bbaf4a3efaf7744d97d109982af4ef58f0efaaa3f6f53</originalsourceid><addsrcrecordid>eNp9kdtKAzEQhoMotlZfwAspeOPN1pw22b0RiniCooL1OmSzkxrZbmqyFXx7s9QDikgYEma-f5jJj9AhwROCsTyNBAuKM9yHYAXN-BYaklyyjOai2EZDTER6EyIGaC_GZ4xxKYnYRQNGhSR5wYfo7D6AhRCgHt_61rWvOrpXGM8hdq5djK0PfV43xj_5xpnxQwe680-w0p3rXNxHO1Y3EQ4-7hF6vLyYn19ns7urm_PpLDOc0y5jzNA6Z9xWVNbGkEqXvKq05ZqB1VZKzutS1gSXZUFTGmxeWJxKWjMrbM5G6GTTdxX8yzoNp5YuGmga3YJfR0U55ZwXGPfo8S_02a9DWqGnJOG5FLL4pha6AeVa67ugTd9UTSWhJcsJk4ma_EGlU8PSGd-CdSn_Q0A3AhN8jOlr1Sq4pQ5vimDVm6Y2pincR2-a4kl09DHxulpC_SX5dCkBbAPEVGoXEL5X-qftO9cSoL8</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2471457678</pqid></control><display><type>article</type><title>Preferred Noninvasive Testing for Nonalcoholic Steatohepatitis</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Le, Long ; Kullar, Ravina ; Saleh, Hussein M. ; Saab, Sammy</creator><creatorcontrib>Le, Long ; Kullar, Ravina ; Saleh, Hussein M. ; Saab, Sammy</creatorcontrib><description>Background There has been an increased interest in the use of noninvasive tests (NITs) to identify advanced liver fibrosis in patients with nonalcoholic fatty liver disease (NALFD). The aim of our study was to define the change in tests’ characteristics (sensitivity and specificity) of different combinations of NITs to detect advanced fibrosis in NAFLD. Methods We stratified NITs into first and second tiers and compared two different strategies of combining NITs to screen for advanced fibrosis in patients with NAFLD. One strategy was using NITs in parallel, and the other was using NITs sequentially. Within both of these strategies, there were two ways of interpreting the overall results. The first way was called “the AND rule,” where a positive result required both individual test results to be positive. The second way was called “the OR rule,” where a positive result required only one individual test to be positive. Accuracy of NITs was obtained from the literature search. Combined accuracy and likelihood ratio (LR) were calculated. Results Combination testing with parallel and sequential order testing under the AND Rule resulted in overall higher specificity and LR+ then using the NITs alone. Specificity ranged from 0.91 to 0.99, and LR+ from 9.3 to 68.6. The subsequent use of MRE was associated with LR+ between 36 and 69. Sensitivity was higher with parallel and sequential order testing under the OR Rule. LR+ ranged from 1.4 to 7.5, and sensitivity from 0.82 to 0.98. Conclusion Screening for advanced fibrosis should be performed sequentially, with positive results confirmed by additional testing. Specificity and LR+ were highest when MRE was employed as the confirmatory test.</description><identifier>ISSN: 0163-2116</identifier><identifier>EISSN: 1573-2568</identifier><identifier>DOI: 10.1007/s10620-020-06382-4</identifier><identifier>PMID: 32671584</identifier><language>eng</language><publisher>New York: Springer US</publisher><subject>Accuracy ; Biochemistry ; Biopsy ; Biopsy - methods ; Clinical Decision Rules ; Comparative analysis ; Elasticity Imaging Techniques - methods ; Gastroenterology ; Hepatology ; Humans ; Laboratories ; Liver ; Liver - diagnostic imaging ; Liver - pathology ; Liver Cirrhosis - diagnosis ; Liver Cirrhosis - etiology ; Liver diseases ; Mass Screening - methods ; Medicine ; Medicine &amp; Public Health ; Mortality ; Non-alcoholic Fatty Liver Disease - complications ; Non-alcoholic Fatty Liver Disease - diagnosis ; Oncology ; Original Article ; Sensitivity and Specificity ; Transplant Surgery</subject><ispartof>Digestive diseases and sciences, 2020-12, Vol.65 (12), p.3719-3725</ispartof><rights>Springer Science+Business Media, LLC, part of Springer Nature 2020</rights><rights>COPYRIGHT 2020 Springer</rights><rights>Springer Science+Business Media, LLC, part of Springer Nature 2020.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c442t-33c2d534fb27dcc1ba94bbaf4a3efaf7744d97d109982af4ef58f0efaaa3f6f53</citedby><cites>FETCH-LOGICAL-c442t-33c2d534fb27dcc1ba94bbaf4a3efaf7744d97d109982af4ef58f0efaaa3f6f53</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s10620-020-06382-4$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s10620-020-06382-4$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32671584$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Le, Long</creatorcontrib><creatorcontrib>Kullar, Ravina</creatorcontrib><creatorcontrib>Saleh, Hussein M.</creatorcontrib><creatorcontrib>Saab, Sammy</creatorcontrib><title>Preferred Noninvasive Testing for Nonalcoholic Steatohepatitis</title><title>Digestive diseases and sciences</title><addtitle>Dig Dis Sci</addtitle><addtitle>Dig Dis Sci</addtitle><description>Background There has been an increased interest in the use of noninvasive tests (NITs) to identify advanced liver fibrosis in patients with nonalcoholic fatty liver disease (NALFD). The aim of our study was to define the change in tests’ characteristics (sensitivity and specificity) of different combinations of NITs to detect advanced fibrosis in NAFLD. Methods We stratified NITs into first and second tiers and compared two different strategies of combining NITs to screen for advanced fibrosis in patients with NAFLD. One strategy was using NITs in parallel, and the other was using NITs sequentially. Within both of these strategies, there were two ways of interpreting the overall results. The first way was called “the AND rule,” where a positive result required both individual test results to be positive. The second way was called “the OR rule,” where a positive result required only one individual test to be positive. Accuracy of NITs was obtained from the literature search. Combined accuracy and likelihood ratio (LR) were calculated. Results Combination testing with parallel and sequential order testing under the AND Rule resulted in overall higher specificity and LR+ then using the NITs alone. Specificity ranged from 0.91 to 0.99, and LR+ from 9.3 to 68.6. The subsequent use of MRE was associated with LR+ between 36 and 69. Sensitivity was higher with parallel and sequential order testing under the OR Rule. LR+ ranged from 1.4 to 7.5, and sensitivity from 0.82 to 0.98. Conclusion Screening for advanced fibrosis should be performed sequentially, with positive results confirmed by additional testing. Specificity and LR+ were highest when MRE was employed as the confirmatory test.</description><subject>Accuracy</subject><subject>Biochemistry</subject><subject>Biopsy</subject><subject>Biopsy - methods</subject><subject>Clinical Decision Rules</subject><subject>Comparative analysis</subject><subject>Elasticity Imaging Techniques - methods</subject><subject>Gastroenterology</subject><subject>Hepatology</subject><subject>Humans</subject><subject>Laboratories</subject><subject>Liver</subject><subject>Liver - diagnostic imaging</subject><subject>Liver - pathology</subject><subject>Liver Cirrhosis - diagnosis</subject><subject>Liver Cirrhosis - etiology</subject><subject>Liver diseases</subject><subject>Mass Screening - methods</subject><subject>Medicine</subject><subject>Medicine &amp; Public Health</subject><subject>Mortality</subject><subject>Non-alcoholic Fatty Liver Disease - complications</subject><subject>Non-alcoholic Fatty Liver Disease - diagnosis</subject><subject>Oncology</subject><subject>Original Article</subject><subject>Sensitivity and Specificity</subject><subject>Transplant Surgery</subject><issn>0163-2116</issn><issn>1573-2568</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp9kdtKAzEQhoMotlZfwAspeOPN1pw22b0RiniCooL1OmSzkxrZbmqyFXx7s9QDikgYEma-f5jJj9AhwROCsTyNBAuKM9yHYAXN-BYaklyyjOai2EZDTER6EyIGaC_GZ4xxKYnYRQNGhSR5wYfo7D6AhRCgHt_61rWvOrpXGM8hdq5djK0PfV43xj_5xpnxQwe680-w0p3rXNxHO1Y3EQ4-7hF6vLyYn19ns7urm_PpLDOc0y5jzNA6Z9xWVNbGkEqXvKq05ZqB1VZKzutS1gSXZUFTGmxeWJxKWjMrbM5G6GTTdxX8yzoNp5YuGmga3YJfR0U55ZwXGPfo8S_02a9DWqGnJOG5FLL4pha6AeVa67ugTd9UTSWhJcsJk4ma_EGlU8PSGd-CdSn_Q0A3AhN8jOlr1Sq4pQ5vimDVm6Y2pincR2-a4kl09DHxulpC_SX5dCkBbAPEVGoXEL5X-qftO9cSoL8</recordid><startdate>20201201</startdate><enddate>20201201</enddate><creator>Le, Long</creator><creator>Kullar, Ravina</creator><creator>Saleh, Hussein M.</creator><creator>Saab, Sammy</creator><general>Springer US</general><general>Springer</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20201201</creationdate><title>Preferred Noninvasive Testing for Nonalcoholic Steatohepatitis</title><author>Le, Long ; Kullar, Ravina ; Saleh, Hussein M. ; Saab, Sammy</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c442t-33c2d534fb27dcc1ba94bbaf4a3efaf7744d97d109982af4ef58f0efaaa3f6f53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Accuracy</topic><topic>Biochemistry</topic><topic>Biopsy</topic><topic>Biopsy - methods</topic><topic>Clinical Decision Rules</topic><topic>Comparative analysis</topic><topic>Elasticity Imaging Techniques - methods</topic><topic>Gastroenterology</topic><topic>Hepatology</topic><topic>Humans</topic><topic>Laboratories</topic><topic>Liver</topic><topic>Liver - diagnostic imaging</topic><topic>Liver - pathology</topic><topic>Liver Cirrhosis - diagnosis</topic><topic>Liver Cirrhosis - etiology</topic><topic>Liver diseases</topic><topic>Mass Screening - methods</topic><topic>Medicine</topic><topic>Medicine &amp; Public Health</topic><topic>Mortality</topic><topic>Non-alcoholic Fatty Liver Disease - complications</topic><topic>Non-alcoholic Fatty Liver Disease - diagnosis</topic><topic>Oncology</topic><topic>Original Article</topic><topic>Sensitivity and Specificity</topic><topic>Transplant Surgery</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Le, Long</creatorcontrib><creatorcontrib>Kullar, Ravina</creatorcontrib><creatorcontrib>Saleh, Hussein M.</creatorcontrib><creatorcontrib>Saab, Sammy</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing &amp; Allied Health Database</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>Consumer Health Database</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Digestive diseases and sciences</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Le, Long</au><au>Kullar, Ravina</au><au>Saleh, Hussein M.</au><au>Saab, Sammy</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Preferred Noninvasive Testing for Nonalcoholic Steatohepatitis</atitle><jtitle>Digestive diseases and sciences</jtitle><stitle>Dig Dis Sci</stitle><addtitle>Dig Dis Sci</addtitle><date>2020-12-01</date><risdate>2020</risdate><volume>65</volume><issue>12</issue><spage>3719</spage><epage>3725</epage><pages>3719-3725</pages><issn>0163-2116</issn><eissn>1573-2568</eissn><abstract>Background There has been an increased interest in the use of noninvasive tests (NITs) to identify advanced liver fibrosis in patients with nonalcoholic fatty liver disease (NALFD). The aim of our study was to define the change in tests’ characteristics (sensitivity and specificity) of different combinations of NITs to detect advanced fibrosis in NAFLD. Methods We stratified NITs into first and second tiers and compared two different strategies of combining NITs to screen for advanced fibrosis in patients with NAFLD. One strategy was using NITs in parallel, and the other was using NITs sequentially. Within both of these strategies, there were two ways of interpreting the overall results. The first way was called “the AND rule,” where a positive result required both individual test results to be positive. The second way was called “the OR rule,” where a positive result required only one individual test to be positive. Accuracy of NITs was obtained from the literature search. Combined accuracy and likelihood ratio (LR) were calculated. Results Combination testing with parallel and sequential order testing under the AND Rule resulted in overall higher specificity and LR+ then using the NITs alone. Specificity ranged from 0.91 to 0.99, and LR+ from 9.3 to 68.6. The subsequent use of MRE was associated with LR+ between 36 and 69. Sensitivity was higher with parallel and sequential order testing under the OR Rule. LR+ ranged from 1.4 to 7.5, and sensitivity from 0.82 to 0.98. Conclusion Screening for advanced fibrosis should be performed sequentially, with positive results confirmed by additional testing. Specificity and LR+ were highest when MRE was employed as the confirmatory test.</abstract><cop>New York</cop><pub>Springer US</pub><pmid>32671584</pmid><doi>10.1007/s10620-020-06382-4</doi><tpages>7</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0163-2116
ispartof Digestive diseases and sciences, 2020-12, Vol.65 (12), p.3719-3725
issn 0163-2116
1573-2568
language eng
recordid cdi_proquest_miscellaneous_2424448005
source MEDLINE; SpringerLink Journals - AutoHoldings
subjects Accuracy
Biochemistry
Biopsy
Biopsy - methods
Clinical Decision Rules
Comparative analysis
Elasticity Imaging Techniques - methods
Gastroenterology
Hepatology
Humans
Laboratories
Liver
Liver - diagnostic imaging
Liver - pathology
Liver Cirrhosis - diagnosis
Liver Cirrhosis - etiology
Liver diseases
Mass Screening - methods
Medicine
Medicine & Public Health
Mortality
Non-alcoholic Fatty Liver Disease - complications
Non-alcoholic Fatty Liver Disease - diagnosis
Oncology
Original Article
Sensitivity and Specificity
Transplant Surgery
title Preferred Noninvasive Testing for Nonalcoholic Steatohepatitis
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T09%3A40%3A44IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Preferred%20Noninvasive%20Testing%20for%20Nonalcoholic%20Steatohepatitis&rft.jtitle=Digestive%20diseases%20and%20sciences&rft.au=Le,%20Long&rft.date=2020-12-01&rft.volume=65&rft.issue=12&rft.spage=3719&rft.epage=3725&rft.pages=3719-3725&rft.issn=0163-2116&rft.eissn=1573-2568&rft_id=info:doi/10.1007/s10620-020-06382-4&rft_dat=%3Cgale_proqu%3EA712935137%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2471457678&rft_id=info:pmid/32671584&rft_galeid=A712935137&rfr_iscdi=true